BETA
Your AI-Trained Oncology Knowledge Connection!
Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma
The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM
Results from part 1 dose level G of the MagnetisMM-6 trial found elranatamab, daratumumab, and lenalidomide to be safe and manageable in NDMM.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM
Results from the PERSEUS trial support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in transplant-eligible NDMM.
Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups
Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.